ClinicalTrials.gg
RecruitingNCT06559332CATUpdated May 8, 2026

Coronary Artery Disease Assessment Strategies in TAVI Patients

An interventional study of Risk-based CAD management and Invasive coronary angiography in Transcatheter Aortic Valve Replacement, Coronary Artery Disease and Heart Disease Risk Factors, sponsored by Insel Gruppe AG, University Hospital Bern. Recruiting at 1 site in Switzerland. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Insel Gruppe AG, University Hospital Bern · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
546
Allocation
Randomized
Ages
70 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 34 studies in Coronary Artery Disease by Insel Gruppe AG, University Hospital Bern — 6 open to participants now, 6 under way, none of them phase 3. Coronary Artery Disease · Insel Gruppe AG, University Hospital Bern.

Planned enrollment
5th of 23
546 · median 100
Started
2025
with 1 other
No phase
18 of 34
4 open now
Registered
33rd of 34
by date

Among the 34 studies in Coronary Artery Disease by Insel Gruppe AG, University Hospital Bern, this one is the 5th largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2025, is one of 18 with no phase, and was the 33rd registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

6 of the 34 studies in Coronary Artery Disease by Insel Gruppe AG, University Hospital Bern are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 70 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Coronary Artery Disease by Insel Gruppe AG, University Hospital Bern, or all of them as a file.
02

Study summary

Coronary artery disease (CAD) and aortic stenosis frequently coincide. Before valve intervention, invasive coronary angiography is routinely performed to assess coronary status.

As the impact of percutaneous revascularization on clinical outcomes beyond symptom improvement is subject to debate and treatment of aortic stenosis itself reduces ischemic burden and symptoms, the benefit/risk balance of routine invasive coronary angiography prior to transcatheter aortic valve implantation (TAVI) is unclear.

The CAT Trial aims to compare a non-invasive risk management strategy to routine invasive coronary angiography for the assessment of coronary artery disease in patients with severe, symptomatic aortic stenosis selected to undergo TAVI with respect to adverse clinical outcomes at 3 years (primary objective) and patient reported outcome measures (secondary objective).

03

Conditions studied

  • Transcatheter Aortic Valve Replacement
  • Coronary Artery Disease
  • Heart Disease Risk Factors
04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Severe aortic stenosis defined by aortic valve area (AVA) ≤1cm2 AND mean gradient ≥40 mmHg or peak velocity ≥4.0 m/s

OR

if mean gradient \<40 mmHg and peak velocity (Vmax) \<4 m/s and stroke volume indexed to body surface area (SVi) ≤ 35 mL/m2 and ≥50% then if CT-derived aortic valve calcium score >2000 Agatston units in men, >1200 in women

OR

if mean gradient \<40 mmHg and Vmax \<4 m/s and SVi ≤ 35 mL/m2 and LVEF \<50% then if CT-derived aortic valve calcification >2000 Agatston units in men, >1200 in women OR if low-dose dobutamine stress echocardiography with flow reserve (>20% increase in stroke volume) and AVA ≤1cm2

  • Coronary calcium score ≥ 400 Agatston units (derived from routine pre-TAVI CT) or known coronary artery disease
  • Selected for treatment with transfemoral TAVI.
  • Written .

Exclusion criteria

Exclusion Criteria:

  • Concomitant valvular heart disease or ascending aortic aneurysm with indication for surgery or intervention
  • Unprotected left main coronary stenosis >50% or left main not evaluable based on coronary computed tomography angiography derived from routine pre-TAVI CT
  • (LVEF) \< 30%
  • New regional wall motion abnormalities on echocardiography
  • Myocardial infarction in previous 12 months
  • Coronary angiography in previous 12 months
  • Prior left main stenting
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
546 participants (estimated)

Study arms

  • Experimental
    Risk-based management strategy without invasive coronary angiography

    Patients will not undergo routine coronary angiography prior to TAVI. Statin treatment of at least moderate intensity is recommended.

    Diagnostic Test: Risk-based CAD management

  • Other
    Routine invasive coronary angiography

    Routine invasive coronary angiography prior to TAVI. Percutaneous coronary intervention (PCI) recommended for coronary diameter stenosis of ≥ 80% (visual angiographic assessment) in coronary segments with a reference vessel diameter of at least 2.5 mm. Timing of PCI at the operators' discretion.

    Diagnostic Test: Invasive coronary angiography

Interventions

  • Diagnostic testRisk-based CAD management

    Patients will not undergo routine coronary angiography prior to TAVI. Statin treatment of at least moderate intensity is recommended.

  • Diagnostic testInvasive coronary angiography

    Routine invasive coronary angiography prior to TAVI. PCI recommended for coronary diameter stenosis of ≥ 80% (visual angiographic assessment) in coronary segments with a reference vessel diameter of at least 2.5 mm. Timing of PCI at the operators' discretion.

06

What researchers measure

Primary outcomes

  1. Composite of all-cause death, myocardial infarction, any stroke, and heart failure hospitalization

    Primary endpoint. Valve Academic Research Consortium (VARC)-3 definitions)

    Time frame: 3 years

Secondary outcomes

  1. Patient reported health status

    Seattle Angina Questionnaire-7 (score from 0 to 100, with higher values indicating better health)

    Time frame: 3 months, 1, 3 and 5 years

  2. Patient reported health status

    Kansas City Cardiomyopathy Questionnaire-12 (score from 0 to 100, with higher values indicating better health)

    Time frame: 3 months, 1, 3 and 5 years

  3. Patient reported health status

    EuroQol 5D 5L (index scores range from -0.59 to 1, with higher values indicating better health)

    Time frame: 3 months, 1, 3 and 5 years

  4. Rate of all cause death

    Time frame: 3 months, 1, 3 and 5 years

  5. Rate of cardiovascular death

    (VARC-3)

    Time frame: 3 months, 1, 3 and 5 years

  6. Rate of disabling strokes

    (VARC-3)

    Time frame: 3 months, 1, 3 and 5 years

  7. Rate of myocardial infarction

    (VARC-3)

    Time frame: 3 months, 1, 3 and 5 years

  8. Rate of unplanned, urgent revascularization

    Time frame: 3 months, 1, 3 and 5 years

  9. Rate of elective revascularization

    Time frame: 3 months, 1, 3 and 5 years

  10. Rate of cardiovascular hospitalization

    Time frame: 3 months, 1, 3 and 5 years

  11. Rate of heart failure hospitalization

    Time frame: 3 months, 1, 3 and 5 years

  12. Rate of bleeding

    (VARC-3)

    Time frame: 3 months, 1, 3 and 5 years

  13. Rate of acute kidney injury

    (VARC-3)

    Time frame: 3 months, 1, 3 and 5 years

  14. Rate of tachyarrhythmia

    (VARC-3)

    Time frame: 3 months, 1, 3 and 5 years

  15. Rate of major vascular complications

    (VARC-3)

    Time frame: 3months, 1, 3 and 5 years

  16. Rate of major cardiac structural complications

    (VARC-3)

    Time frame: 3 months, 1, 3 and 5 years

  17. Rate of permanent pacemaker implantation

    (VARC-3)

    Time frame: 3 months, 1, 3 and 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — sharing via https://boris.unibe.ch platform

Supporting information: Study protocol, Clinical study report

Time frame: after study completion

Access criteria: Data will be made available upon reasonable request

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Mar 2030, 60 months after the start.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 60 months is above that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2024
First posted
Aug 19, 2024
StartActual
Mar 11, 2025
Primary completionEst.
Mar 31, 2030
CompletionEst.
Mar 31, 2032
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06559332
Collaborators
Clinical Trials Unit Bern (CTU), Schweizerische Herzstiftung
Responsible party
Sponsor
First posted
Aug 19, 2024
Start date
Mar 11, 2025
Primary completion
Mar 31, 2030 (estimated)
Completion
Mar 31, 2032 (estimated)
Last update
May 8, 2026

Study contacts

Jonas Lanz, MD MSc
Contact
jonas.lanz@insel.ch
+41 31 632 21 11
Thomas Pilgrim, MD MPH
Contact
Jonas Lanz, MD, MSc
principal investigator · University of Bern

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion